Taysha Gene Therapies Inc


Prices are adjusted according to historical splits.

Taysha Gene Therapies Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$678.66 million
Book Value:
Revenue TTM:
$9.60 million
Operating Margin TTM:
Gross Profit TTM:
$2.50 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Taysha Gene Therapies Inc had its IPO on 2020-09-24 under the ticker symbol TSHA.

The company operates in the Healthcare sector and Biotechnology industry. Taysha Gene Therapies Inc has a staff strength of 65 employees.

Stock update

Shares of Taysha Gene Therapies Inc opened at $3.45 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.95 - $3.45, and closed at $3.02.

This is a -13.71% slip from the previous day's closing price.

A total volume of 4,805,593 shares were traded at the close of the day’s session.

In the last one week, shares of Taysha Gene Therapies Inc have slipped by -16.8%.

Taysha Gene Therapies Inc's Key Ratios

Taysha Gene Therapies Inc has a market cap of $678.66 million, indicating a price to book ratio of 13.3011 and a price to sales ratio of 0.

In the last 12-months Taysha Gene Therapies Inc’s revenue was $9.60 million with a gross profit of $2.50 million and an EBITDA of $-77633000. The EBITDA ratio measures Taysha Gene Therapies Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Taysha Gene Therapies Inc’s operating margin was -822.1% while its return on assets stood at -44.08% with a return of equity of -745.28%.

In Q2, Taysha Gene Therapies Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Taysha Gene Therapies Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Taysha Gene Therapies Inc’s profitability.

Taysha Gene Therapies Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.1345. Its price to sales ratio in the trailing 12-months stood at 0.

Taysha Gene Therapies Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$81.54 million
Total Liabilities
$50.64 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Taysha Gene Therapies Inc ended 2023 with $81.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $81.54 million while shareholder equity stood at $-37114000.00.

Taysha Gene Therapies Inc ended 2023 with $6.21 million in deferred long-term liabilities, $50.64 million in other current liabilities, 1000.00 in common stock, $-443661000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $45.08 million and cash and short-term investments were $45.08 million. The company’s total short-term debt was $1,638,000 while long-term debt stood at $38.35 million.

Taysha Gene Therapies Inc’s total current assets stands at $54.12 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $10.77 million and inventory worth $0.

In 2023, Taysha Gene Therapies Inc's operating cash flow was $48000.00 while its capital expenditure stood at $48000.

Comparatively, Taysha Gene Therapies Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Taysha Gene Therapies Inc stock is currently trading at $3.02 per share. It touched a 52-week high of $3.89 and a 52-week low of $3.89. Analysts tracking the stock have a 12-month average target price of $5.72.

Its 50-day moving average was $1.55 and 200-day moving average was $1.29 The short ratio stood at 0.08 indicating a short percent outstanding of 0%.

Around 3933.1% of the company’s stock are held by insiders while 2868.5% are held by institutions.

Frequently Asked Questions About Taysha Gene Therapies Inc

The stock symbol (also called stock or share ticker) of Taysha Gene Therapies Inc is TSHA

The IPO of Taysha Gene Therapies Inc took place on 2020-09-24

Similar Industry Stocks (Biotechnology)

Last Price
Akanda Corp (AKAN)
Hemo Organic Limited (HEMORGANIC)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.


3000 Pegasus Park Drive, Dallas, TX, United States, 75247